Previously submitted to: Journal of Medical Internet Research (no longer under consideration since Nov 25, 2022)
Date Submitted: Oct 29, 2022
Open Peer Review Period: Oct 28, 2022 - Nov 25, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huayan Capsules in the treatment of osteosarcoma
ABSTRACT
Background:
Huayan Capsules (HYCA) has adjuvant therapeutic effect to the patients with OS in China, which is based on our hospital long-term clinical practice. Network pharmacology is a theory based on systems biology that helps to reveal the underlying mechanisms of action between drugs and disease development.
Objective:
Osteosarcoma (OS) is the most frequent primary bone sarcomas. It is commonly found in the long bones of the limbs of the human body. The purpose of study was to explore the active ingredients, targets and mechanism of HYCA in the treatment of OS through network pharmacology and molecular docking technology.
Methods:
TCMSP and TCMID database were used to obtain the active ingredients and targets of HYCA. Targets related to OS were obtained by GeneCards, TTD and OMIM. The related target protein network was constructed and analyzed for Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. The compound was molecularly docked with proteins associated with OS by using AutoDock Vina.
Results:
In this study, we searched that HYCA has 239 active compounds, 1703 targets and of HYCA. Meanwhile, there was 220 intersection targets of OS and HYCA. Construction of protein-protein interactions (PPI) network analysis showed that there were 25 key targets of HYCA in the treatment of OS including TP53, AKT1, etc. GO enrichment analysis mainly including cell response to hormones and other compounds. KEGG enrichment analysis obtained 196 signaling pathways, which mainly including pathways in cancer, PI3K-Aktsignaling pathway, MAPK signaling pathway. Molecular docking showed that quercetin, kamanol and luteolin have strong binding ability with AKT1, TP53.
Conclusions:
HYCA may treat OS by regulating the pathways in cancer, PI3K-Akt and MAPK signaling pathway. We will demonstrate the relationship among the active compounds of HYCA, TCM classification of OS and signal pathway, so as to provide a systematic TCM treatment plan for the clinical treatment of OS.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.